Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03046979
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Study Details

The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.

Key Dates

Start date
Dec 31, 2016
Status verified
Jan 2017
Primary completion
Dec 31, 2017
Completion
Dec 31, 2018

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.

Primary Outcome Measure

Objective Response Rate(ORR) [ Time Frame: one year ]

Central Contacts

Related Studies